Articles

For the first time, a novel gamma secretase inhibitor has shown extremely promising results in desmoid tumors—a rare, benign, but potentially aggressive tumor type

The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer.

More than 50% of adults with refractory or relapsed large B-cell lymphoma (LBCL) who were not deemed candidates for high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) had complete responses (CRs) following treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi).

Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy.

Cancer growth and oncology care did not stop during the COVID-19 pandemic, and oncologists, healthcare workers, and patients came together to overcome challenges and produce incredible solutions that may be with us for many years.

On September 30, 2022, the FDA accelerated the approval of futibatinib (Lytgobi; Taiho Oncology), a tyrosine kinase inhibitor, for the treatment of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (CCA) in adults with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other arrangements.

On August 10, 2022, the FDA accelerated the regular full approval of capmatinib (Tabrecta; Novartis), a tyrosine kinase inhibitor, for the treatment of metastatic non–small-cell lung cancer (NSCLC) in adults whose tumors have MET exon 13 skipping mutation, as detected by an FDA-approved test.

On September 21, 2022, the FDA accelerated the approval of selpercatinib (Retevmo; Eli Lilly), a RET kinase inhibitor, for the treatment of locally advanced or metastatic solid tumors with a RET gene fusion in patients whose disease has progressed while or after receiving systemic treatment or who have no alternative treatment options.

On September 2, 2022, the FDA accelerated the approval of durvalumab (Imfinzi; AstraZeneca), a PD-L1–blocking antibody, in combination with gemcitabine and cisplatin, for the treatment of locally advanced or metastatic biliary tract cancer in adults.

On August 26, 2022, the FDA accelerated the approval of pemigatinib (Pemazyre; Incyte Corporation), a tyrosine kinase inhibitor, for the treatment of relapsed or refractory myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR)1 rearrangement in adults.